Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Monina Jao

Internal Medicine Martins Ferry, OH Medical Doctor

NPI 1619080314 CMS profile 254832

92 N 4Th St, Ste 29, Martins Ferry, OH 43935

Open in the dashboard

General payments

$18,534

847 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monina Jao of Martins Ferry, OH is reported in the CMS Open Payments database as having received $18,534 across 847 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,179 77
2024 General $3,214 106
2023 General $2,333 96
2022 General $2,627 127
2021 General $2,533 155
2020 General $2,526 148
2019 General $3,121 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monina Jao
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Monina Jao were reported at $2,179. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Monina Jao Internal Medicine median Middle half National median
2019 $3,121 $159 $48–$570 $163
2020 $2,526 $119 $33–$402 $114
2021 $2,533 $135 $37–$521 $132
2022 $2,627 $141 $42–$496 $149
2023 $2,333 $149 $45–$519 $160
2024 $3,214 $154 $47–$537 $164
2025 $2,179 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,692 100 payments
  2. Novo Nordisk Inc $2,470 147 payments
  3. AbbVie, Inc. $2,391 102 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $1,338 59 payments
  5. Pfizer Inc. $897 40 payments
  6. Janssen Pharmaceuticals, Inc $792 27 payments
  7. Lilly USA, LLC $706 48 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $598 38 payments
  9. Merck Sharp & Dohme Corporation $564 31 payments
  10. GlaxoSmithKline, LLC. $470 17 payments
  11. Other $5,616 238 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,529 846 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $1,775 117 payments
  2. Kerendia $1,338 59 payments
  3. RYBELSUS $1,317 88 payments
  4. QULIPTA $1,149 33 payments
  5. AIRSUPRA $857 37 payments
  6. FARXIGA $831 33 payments
  7. UBRELVY $648 23 payments
  8. BREZTRI $617 14 payments
  9. ELIQUIS $559 27 payments
  10. LINZESS $540 32 payments
  11. Other $12,689 646 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 286 drugs

Part D claims

23,388

Median for Internal Medicine: 777

Drug cost

$2,477,842

Median for Internal Medicine: $73,373

Branded share of claims

24.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 390 $233,911
Ozempic Semaglutide Brand 134 $184,716
Farxiga Dapagliflozin Propanediol Brand 201 $149,740
Mounjaro Tirzepatide Brand 91 $110,631
Xarelto Rivaroxaban Brand 148 $99,137
Invega Sustenna Paliperidone Palmitate Brand 30 $89,076
Trulicity Dulaglutide Brand 96 $86,486
Kerendia Finerenone Brand 60 $85,847
Humira(Cf) Pen Adalimumab Brand 11 $76,804
Jardiance Empagliflozin Brand 85 $74,962

The 10 drugs with the highest cost, of 286 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$256,089

Of which drugs: $688

Medicare patients

463

Average age 73

Services billed

3,581

267 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%
Arthritis 51%
Chronic kidney disease 43%
Heart failure 42%
Depression 42%
Ischemic heart disease 41%
Atrial fibrillation 38%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 31 31 $664

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$549 — —
Kerendia
$435 60 —
BREZTRI
$282 36 —
QULIPTA
$281 — —
Korlym
$166 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

847 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record